Visceral Manifold Study for the Repair of TAAA
Key facts
- Who runs it
- University of South Florida
- Where
- Tampa, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 15 people, planned
- Started
- 19 Dec 2017
- Expected to end
- 1 Feb 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- TAAA Debranching Stent Graft System
- Record updated
- 22 January 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- A patient may be entered into the study if the patient has at least one of the following:; An aneurysm with a maximum diameter of > 5.5 cm or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements; Aneurysm with a history of growth > 0.5 cm in 6 months; Saccular aneurysm deemed at significant risk for rupture; Symptomatic aneurysm greater than 4.5 cm
- Axillary or brachial and iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit
- Proximal landing zone for the thoracic bifurcation stent graft that has:; ≥ 2.5 cm of nonaneurysmal aortic segment including previously placed graft material (neck) distal to the left subclavian artery (LSA) diameter in the range of 26-42 mm; Adequate distance from the celiac artery, in order to accommodate cannulation from the antegrade access point when considering the total deployed length of the thoracic bifurcation and visceral manifold
- Minimum branch vessel diameter greater than 5 mm
- Iliac artery or aortic distal fixation site, including both native tissue and previously placed graft, greater than or equal to 15 mm in length and diameter in the range of 8 - 25 mm
- Age: ≥ 18 years old
- Life expectancy: > 1 year
- Patient that meets the criteria for inclusion in the primary study arm but has one or more of the following criteria which would exclude them from the primary study arm:; Minimum branch vessel diameter less than 5 mm; Urgent or emergent presentation; Patient has a contained rupture; Patient has a ruptured aneurysm; Patient has a type B dissection (subacute or chronic) in the portion of the aorta intended to be treated; Poor performance status including two major system failures (cardiovascular, pulmonary, renal, hepatobiliary, and neuromuscular); Baseline creatinine greater than 2.0 mg/dL; Anatomy that would not allow for maintenance of at least one hypogastric artery; Anatomy that would not allow for primary or assisted patency of the left subclavian artery Or
- Patient that meets the criteria for inclusion in the primary study arm and:; Would not be eligible for the primary study arm per a documented reason other than those outlined above, and; Per the opinion of the Principal Investigator, with concurrence of the IRB, alternative therapies are unsatisfactory and the probable risk of using the investigational device is no greater than the probable risk from the disease or condition
Who cannot take part
- Patient is a good candidate for and elects for open surgical repair
- Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned < 30 days of the endovascular repair
- Known sensitivities or allergies to the materials of construction of the devices, including nitinol (Nickel: Titanium), polyester, platinum-iridium, polytetrafluoroethylene (PTFE), platinum, gold, polyethylene, or stainless steel
- Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
- Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina)
- Systemic or local infection that may increase the risk of endovascular graft infection
- History of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome); Anatomical exclusion criteria
- Baseline creatinine greater than 2.0 mg/dL
- General exclusion
- Can be treated in accordance with the instructions for use with a legally marketed endovascular prosthesis
- Is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site
- Unwilling to comply with the follow-up schedule
- Inability or refusal to give informed consent
- Urgent or emergent presentation
- Patient is pregnant or breastfeeding
- Patient has a contained rupture
- Patient has a ruptured aneurysm
- Patient has a dissection in the portion of the aorta intended to be treated
- Obstructive stenting of any or all of the visceral vessels
- Poor performance status including two major system failures (cardiovascular, pulmonary, renal, hepatobiliary, and neuromuscular); Medical exclusion criteria
- Uncorrectable coagulopathy
- Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
- Thrombus or excessive calcification within the neck of the aneurysm
- Anatomy that would not allow maintenance of at least one patent hypogastric artery
- Anatomy that would not allow primary or assisted patency of the left subclavian artery; Expanded Selection Criteria Subjects who fail to meet inclusion criteria for the primary study arm may be enrolled under an expanded selection arm if they meet the following criteria
Other criteria
- Primary Study Arm
Where in United States
- Tampa General Hospital / University of South FloridaTampa, United States
- University of South Florida - South Tampa CampusTampa, United States
About the trial
What the trial wants to find out
The outcomes from prior clinical evaluation of the study device, including successfully treating 99% (84/85) of the intended target vessels and 96% (27/28) limb patency observed at one year, demonstrate the potential benefits of the device. When contrasted with open repair's significant complication rates and branch fenestrated device's significant anatomic and logistic limitations, the potential risk of the proposed novel graft does not outweigh the potential benefit of widened anatomic availability and improved patency rates. Given the potential benefits, the investigators feel that it is justified to expose the target patient population to the potential risk. The non-clinical testing performed by Medtronic and the clinical results reported by Sanford Health show adequate safety of the device to support an early feasibility study.
Read full original descriptionShow less
The investigators would like to perform an early feasibility study under a defined and controlled protocol to collect prospective preliminary safety and device functionality data. The investigators believe an early feasibility study is most appropriate for this novel approach. The limited sample size allows adequate patient data to be collected under a controlled protocol without exposing a large patient population to the risk associated with a novel device design.
The 2 groups in the trial
- Primary studyTreatment being tested
Patients meeting primary inclusion/exclusion criteria will be enrolled in primary study arm and be treated with the TAAA Debranching Stent Graft System.
Treatment: TAAA Debranching Stent Graft System
- Expanded selectionTreatment being tested
Patients who fail to meet inclusion criteria for the primary study arm may be enrolled under the expanded selection arm and be treated with the TAAA Debranching Stent Graft System.
Treatment: TAAA Debranching Stent Graft System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms
- Record updated
- 22 January 2025